Welcome to our dedicated page for Karuna Therapeutics news (Ticker: KRTX), a resource for investors and traders seeking the latest updates and insights on Karuna Therapeutics stock.
Karuna Therapeutics, Inc. (NASDAQ: KRTX) is an innovative clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for neuropsychiatric conditions with significant unmet medical needs. Our flagship product candidate, KarXT, is an oral modulator of muscarinic receptors, targeting both the central nervous system (CNS) and various peripheral tissues. KarXT uniquely combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS.
Our pipeline capitalizes on the broad therapeutic potential of KarXT. We have assembled a team with extensive expertise in the research, development, and commercialization of CNS agents. This includes deep familiarity with the biology of neuropsychiatric disorders such as schizophrenia and Alzheimer's disease, and the role of muscarinic receptors in their potential treatment.
Recently, Karuna Therapeutics has achieved significant milestones in advancing KarXT through various stages of clinical trials, demonstrating promising results in improving symptoms of schizophrenia and other neuropsychiatric conditions. We are committed to leveraging our deep understanding of CNS biology to develop a pipeline of novel therapies aimed at addressing the pressing needs of patients with debilitating mental health conditions.
In addition to our scientific endeavors, we actively seek strategic partnerships and collaborations to accelerate the development and commercialization of our therapies. Our financial condition remains robust, supported by strategic investments and a clear focus on driving innovation in neuropsychiatric treatment.
Stay updated with the latest news and developments from Karuna Therapeutics, Inc. as we continue our mission to transform the treatment landscape for neuropsychiatric disorders.
Karuna Therapeutics (NASDAQ: KRTX) shared data from the Phase 3 EMERGENT-2 trial of KarXT for schizophrenia at the 35th ECNP Congress in Vienna, from October 15-18, 2022. The presentation highlighted both previously reported and new safety data, reinforcing KarXT's potential as a novel treatment for schizophrenia. The drug, an investigational M1/M4-preferring muscarinic agonist, aims to address unmet needs in schizophrenia treatment due to its unique mechanism of action. Notably, 21 million people globally are affected by schizophrenia, highlighting the significance of effective therapies.
Karuna Therapeutics (NASDAQ: KRTX) has announced that its senior management will present at several investor conferences in September 2022. Key events include Citi’s 17th Annual BioPharma Conference on September 7 at 9:40 a.m. ET, Wells Fargo Healthcare Conference on September 8 at 9:45 a.m. ET, and Morgan Stanley’s 20th Annual Global Healthcare Conference on September 12 at 8:10 a.m. ET. Live webcasts will be accessible on Karuna's Investor Relations page, with archived replays available for 30 days.
Karuna Therapeutics, Inc. (NASDAQ: KRTX) has successfully closed its upsized underwritten public offering of 4,011,628 shares at a price of $215.00 per share, yielding gross proceeds of approximately $862.5 million. This offering included the full exercise of an underwriter option for an additional 523,255 shares. Goldman Sachs & Co. LLC and J.P. Morgan acted as joint book-running managers. The shares were offered under an effective shelf registration statement filed with the SEC. This capital is intended to support Karuna's mission to develop transformative medicines for psychiatric and neurological disorders.
Karuna Therapeutics (NASDAQ: KRTX) announced a public offering of 3,488,373 shares at $215.00 each, expecting gross proceeds of approximately $750 million before expenses. The offering is set to close around August 12, 2022, pending customary conditions. All shares are sold by Karuna, which also provided underwriters a 30-day option for an additional 523,255 shares. The offering is conducted under a previously filed effective shelf registration statement with the SEC, and details are available on their website.
Karuna Therapeutics (NASDAQ: KRTX) announced an underwritten public offering of $600 million of its common stock, with an option for underwriters to purchase an additional $90 million. The offering is subject to market conditions, and all shares will be sold by Karuna. Goldman Sachs & Co. LLC and J.P. Morgan serve as joint book-running managers, with Jefferies also involved. The company plans to file a preliminary prospectus supplement with the SEC. This offering aims to support its mission in developing transformative treatments for psychiatric and neurological conditions.
Karuna Therapeutics announced positive results from its Phase 3 EMERGENT-2 trial for KarXT, a treatment for schizophrenia, showing a significant 9.6-point reduction in PANSS scores versus placebo.
The company plans to submit a New Drug Application to the FDA in mid-2023 and has $407.4 million cash reserves to fund operations for at least the next year. Financial results showed a net loss of $64.9 million in Q2 2022, up from $34.4 million year-on-year, primarily due to increased R&D expenses.
Karuna Therapeutics (KRTX) announced positive topline results from its Phase 3 EMERGENT-2 trial, which evaluated KarXT for treating schizophrenia. The trial achieved its primary endpoint with a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo (p<0.0001). Key secondary endpoints also showed notable reductions in both positive and negative symptoms of schizophrenia. The treatment was generally well tolerated, with adverse effects comparable to placebo. The company plans to submit a New Drug Application to the FDA in mid-2023.
Karuna Therapeutics (NASDAQ: KRTX) announced upcoming presentations at major investor conferences. The William Blair 42nd Annual Growth Stock Conference is set for June 8, 2022, at 5:00 p.m. ET, followed by the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 5:00 p.m. ET. A live webcast will be available on their Investor Relations page, with replays accessible for 30 days. Karuna focuses on developing transformative treatments for psychiatric and neurological conditions.
Karuna Therapeutics (NASDAQ: KRTX) has announced a virtual event on
Karuna Therapeutics (NASDAQ: KRTX) reported a net loss of
FAQ
What is the market cap of Karuna Therapeutics (KRTX)?
What is Karuna Therapeutics, Inc.?
What is KarXT?
What conditions does KarXT aim to treat?
What makes KarXT unique?
Who makes up the team at Karuna Therapeutics?
How is Karuna Therapeutics progressing with KarXT?
What is the financial condition of Karuna Therapeutics?
Does Karuna Therapeutics have any strategic partnerships?
Where can I find the latest news about Karuna Therapeutics?
What is the ticker symbol for Karuna Therapeutics, Inc.?
